CELLDEX THERAPEUTICS INC
CLDXNASDAQTrading Snapshot
- Day Range
- $31.50 – $31.80
- 52-Week Range
- $22.10 – $45.14
- Volume
- $6.00B
- Avg Volume
- $4.64B
- Shares Outstanding
- 66.5M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $22,000
- P/E Ratio
- -7.3
- P/S Ratio
- 18797.1x
- EPS (TTM)
- $-3.86
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.2%
Why Investors Own CLDX
- ✓High-growth profile — revenue up +44.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CELLDEX THERAPEUTICS INC
CLDX
StockOtter · stockotter.spaceAbout CELLDEX THERAPEUTICS INC
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down – What’s Next?
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $37.89, but opened at $36.60. Celldex Therapeutics shares last traded at $35
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
Celldex Therapeutics (NASDAQ: CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Celldex's skin disease drug meets goals in two late-stage trials
Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.